Ligand completes USD 739 million XOMA Royalty acquisition at USD 39 a share

• Ligand Pharmaceuticals completed its acquisition of XOMA Royalty for USD 39 per share in cash, valuing the deal at about USD 739 million.
• XOMA Royalty shareholders also received one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation.
• The deal adds seven commercial royalty products and more than 100 development and commercial-stage assets, taking Ligand’s portfolio above 200 assets.
• Ligand expects the transaction to be immediately accretive, adding about USD 0.5 to 2026 adjusted EPS and USD 1.5 to 2027 adjusted EPS.
• XOMA Royalty shares ceased trading on the Nasdaq Global Market following the closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140900PRIMZONEFULLFEED9761826) on July 14, 2026, and is solely responsible for the information contained therein.